Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.
Also called NCT07045142
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT07045142
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07045142. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-01 (actual); primary completion 2027-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
- Condition
- Schizophrenia
- Intervention (Drug)
- Atorvastatin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Central South University
- Collaborator
- Zhumadian Second People's Hospital
- Collaborator
- Changsha Third Hospital
- Collaborator
- The Second People's Hospital of Dali Bai Autonomous Prefecture
- Collaborator
- Xiangshan County Traditional Chinese Medicine Hospital Medical and Health Group Three Hospitals Distric
- Collaborator
- Yueyang Rehabilitation Hospital
- Collaborator
- Junshan District Psychiatric Rehabilitation Hospital
- Collaborator
- The Second People's Hospital of Xiangyin County
Record details
- Record id
cardio:ct-nct07045142- Content hash
f27f2fbb371e6892c640dfc8060d013a3c561a0539911410ce34fe639604a0db